장마감
로그인 회원가입
LMAT
LMAT
Lemaitre Vascular Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$98.93
+3.34 ▲ +3.49%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$98.93
+0.00 +0.00%

르메트르 혈관(LMAT) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$2.3B
스몰캡
P/E
36.5
적정 수준
배당수익률
1.01%
52주 위치
51%
저점 +25% · 고점 -16%
애널리스트
매수
A-
Fundamental health
vs. Medical Instruments & Supplies
수익성
Top 11%
성장
Top 27%
밸류에이션
Top 31%
재무 안정
Top 18%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 38원. Over the past 5년, it usually traded around 45원. Not because the price dropped, but because earnings grew much faster — this is one of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index RUTP/E 36.45EPS (ttm) 2.71Insider Own 6.9%Shs Outstand 22.9MPerf Week -2.71%
Market Cap 2.26BForward P/E 30.39EPS next Y 8.53%Insider Trans -15.07%Shs Float 21.3MPerf Month 5.32%
Enterprise Value 2.08BPEG 2.6EPS next Q 0.81Inst Own 97.85%Short Float 6.96%Perf Quarter -12.8%
Income 0.06BP/S 8.82EPS this Y 19.04%Inst Trans 2.91%Short Ratio 4.69Perf Half Y 17.47%
Sales 0.26BP/B 5.56EPS next 5Y 11.68%ROA 10.53%Short Interest 1.48MPerf YTD 21.99%
Book/sh 17.8P/C 6.16EPS past 3/5Y 39.34% 19.43%ROE 16.55%52W High -16.17% ($118.01)Perf Year 20.02%
Cash/sh 16.07P/FCF 28.57Sales past 3/5Y 15.58% 14.05%ROIC 10.52%52W Low 25.22% ($79.00)Perf 3Y 58.09%
Dividend Est. $1 (1.01%)EV/EBITDA 24.93EPS Y/Y TTM 36.99%Gross Margin 70.71%Volatility(W/M) 3.36% 3.52%Perf 5Y 82.7%
Dividend TTM 0.9EV/Sales 8.13Sales Y/Y TTM 13.27%Oper. Margin 28.51%ATR (14) 3.68Perf 10Y 576.21%
Dividend Ex-Date 2026/5/21Quick Ratio 12.2EPS Q/Q 41.6%Profit Margin 24.35%RSI (14) 50.06Recom 1.89
Dividend Gr. 3/5Y 16.96% 16.05%Current Ratio 13.93Sales Q/Q 11.16%SMA20 -1.35% ($100.28)Beta 0.53Target Price $118.75
Payout 31.77%Debt/Eq 0.47Earnings 2026/8/4SMA50 1.95% ($97.04)Rel Volume 0.9Prev Close $95.59
Employees 655LT Debt/Eq 0.46EPS/Sales Surpr. 2.94% -0.18%SMA200 3.82% ($95.29)Avg Volume(3M) 0.32MPrice $98.93
IPO 2006/10/19Option/Short Yes/YesTrades 4858Volume 285,167Change 3.49%
Quarterly earnings trend SEC filings · USD
24.3
24.6
24.9
24.12*
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $16M (YoY +42%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Lemaitre Vascular Inc (LMAT) Investment Analysis

What kind of company is Lemaitre Vascular Inc?

르메트르 혈관(LMAT) 방어주
Healthcare · Medical Instruments & Supplies
Healthcare Stocks

🩸 This is a US-based company that develops and supplies medical devices for the treatment of peripheral vascular diseases. It offers a diverse range of niche medical devices used in peripheral vascular surgery, including vascular grafts and shunts, catheters, and patches, and grows through a specialized product portfolio and acquisition strategy targeting vascular surgeons. The company has established itself as a medical device provider focused on the peripheral vascular field.

Learn more about Lemaitre Vascular Inc →
Market Cap
$2.3B
Approx. KRW 3.1 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2011
Employees655people
IPO2006/10/19
Current Price$98.93 ≈ 135,534원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-7
예상 매출 - · EPS $0.81
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 5월 21일 (목) 주당 $1
🔔 Earnings release 2026년 5월 5일 (화) · 장 마감 후 EPS +2.9% 매출 -0.2%
🎯 Ex-div 2026년 3월 12일 (목) 주당 $0.25
🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후 EPS +2.4% 매출 +2.6%

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
28.5%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 5.5% · Top 10%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
24.4%
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median -5.3% · Top 4%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
70.7%
✓ 우수
My positionTop 25%
Low range Average High range
Medical Instruments & Supplies Median 48.6% · Top 10%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
16.6%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -17.0% · Top 18%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
10.5%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -9.3% · Top 12%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
10.5%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -11.9% · Top 14%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.47
✓ Healthy debt
My positionMid-range
Low range Average High range
Medical Instruments & Supplies Median 0.26
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
13.93
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median 2.34
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
12.20
✓ 우수
My positionTop 5%
Low range Average High range
Medical Instruments & Supplies Median 1.97
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$118.75
현재가 대비 +20.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
30.39배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
2.60
고평가
💡 PEG > 2 — 성장 대비 비싼 편
내년 EPS 예상 성장률
+8.5%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+11.7%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+2.7%
평균 서프라이즈
2026.05.05
상회
실적 $0.68 · 예상 $0.66 +3.0%
2026.02.25
상회
실적 $0.68 · 예상 $0.66 +2.4%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+19.0%
우수
My positionTop 25%
Low range Average High range
방어주 중형주 Median 5.2% · Top 17%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+8.5%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 10.7% · Bottom 38%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+11.7%
우수
My positionTop 25%
Low range Average High range
방어주 중형주 Median 7.2% · Top 19%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+39.3%
우수
My positionTop 5%
Low range Average High range
방어주 중형주 Median 4.5% · Top 2%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+19.4%
양호
My positionMid-range
Low range Average High range
방어주 중형주 Median 6.5% · Top 31%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+14.1%
우수
My positionTop 25%
Low range Average High range
방어주 중형주 Median 7.7% · Top 25%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+11.2%
양호
My positionMid-range
Low range Average High range
방어주 중형주 Median 4.6% · Top 31%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Slightly outperformed the market over 5 years (+14%p)
LMAT +82.7% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+14.4%p
ahead of the market
vs Health Care (XLV)
+58.2%p
well ahead of the sector average
1-year basis
vs S&P 500
+4.0%p
roughly in line with the market
vs Health Care (XLV)
+0.3%p
roughly in line with the sector average
Rank among peers
5-year return Top among peers Based on 10 peers
1-year return Top 14% Based on 12 peers
Current position within 52-week range
Low (-25.2%p) High (-16.2%p)
Current price is 25.2% above the 52-week low and 16.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-24.5%
Annualized volatility
40.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $98.93 below the midline ($100.28). Normal downward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.288 · Signal 0.792 · Hist -0.504. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 50.1 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 38.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Pricey
🏢 Vs. Assets Pricey
🧾 Vs. Sales Pricey
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
36.45x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 35.22x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
30.39x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 18.44x · Bottom 24% — expensive within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
5.56x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 2.71x · Bottom 20% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
8.82x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 2.92x · Bottom 25% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
24.93x
✓ Pricey
My positionBottom 25%
Low range Average High range
Medical Instruments & Supplies median 14.76x · Bottom 25% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
28.57x
✓ Fair
My positionMid-range
Low range Average High range
Medical Instruments & Supplies median 25.16x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$118.75 vs. current price +20.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership flow shows some pressure
Insider net selling -15.1% · Institutional net buying +2.9% · Short interest moderate 7.0% · Short interest up +1.1pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-15.1%
Insiders large net selling
🏦 Institutions (funds & investors)
+2.9%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 97.8%
Institution-led, stable structure
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 6.9%
Meaningful insider stake
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
7.0%
Moderate
Healthcare 중형주 Median 11.3%
Past 90 days 📈 +1.1%p increase
Short interest days to cover
4.7 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 22.9M주
Float (tradable shares) 21.3M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding LMAT

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 1.01%
배당보다 주가 성장에 가까운 비중
Dividend Yield
1.01%
Industry average 1.23%
Dividend Per Share
$1.00
Annualized
Payout Ratio
32%
Share of net income paid as dividends
5-Year Growth
16.1%
Annualized dividend growth
🏆 14년 연속 배당 증가
📅 지급월 3월 · 8월 · 11월
📊 총 이력 2011~2026 (61건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.18 +12.5%
2016
$0.22 +22.2%
2017
$0.28 +27.3%
2018
$0.34 +21.4%
2019
$0.38 +11.8%
2020
$0.44 +15.8%
2021
$0.50 +13.6%
2022
$0.56 +12.0%
2023
$0.64 +14.3%
2024
$0.80 +25.0%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 61건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-03-12
$0.250
0.99%
2025-11-20
$0.200
1.14%
2025-08-21
$0.200
0.79%
2025-05-15
$0.200
1.06%
2025-03-13
$0.200
1.07%
2024-11-21
$0.160
0.60%
2024-08-15
$0.160
0.91%
2024-05-15
$0.160
0.95%
2024-03-13
$0.160
0.87%
2023-11-15
$0.140
1.31%
2023-08-16
$0.140
1.20%
2023-05-16
$0.140
1.02%
2023-03-08
$0.140
1.05%
2022-11-16
$0.125
1.34%
2022-08-24
$0.125
1.17%
2022-05-16
$0.125
1.33%
2022-03-07
$0.125
1.22%
2021-11-18
$0.110
1.04%
2021-08-25
$0.110
0.95%
2021-05-18
$0.110
1.05%
2021-03-08
$0.110
0.84%
2020-11-18
$0.095
1.22%
2020-08-26
$0.095
1.18%
2020-05-19
$0.095
1.79%
2020-03-02
$0.095
1.50%
2019-11-19
$0.085
1.19%
2019-08-20
$0.085
1.27%
2019-05-21
$0.085
1.43%
2019-03-21
$0.085
1.17%
2018-11-19
$0.070
1.22%
2018-08-21
$0.070
0.85%
2018-05-21
$0.070
0.90%
2018-03-21
$0.070
0.64%
2017-11-21
$0.055
0.63%
2017-08-21
$0.055
0.62%
2017-05-22
$0.055
0.83%
2017-03-20
$0.055
0.79%
2016-11-17
$0.045
0.89%
2016-08-18
$0.045
1.01%
2016-05-23
$0.045
1.13%
2016-03-17
$0.045
1.54%
2015-11-18
$0.040
1.36%
2015-08-18
$0.040
1.34%
2015-05-20
$0.040
1.82%
2015-03-18
$0.040
2.25%
2014-11-18
$0.035
2.41%
2014-08-19
$0.035
2.20%
2014-05-20
$0.035
2.03%
2014-03-18
$0.035
1.93%
2013-11-18
$0.030
1.45%
2013-08-19
$0.030
1.67%
2013-05-20
$0.030
1.77%
2013-03-18
$0.030
1.76%
2012-11-16
$0.025
1.91%
2012-08-15
$0.025
1.84%
2012-05-16
$0.025
2.12%
2012-03-16
$0.025
1.91%
2011-11-21
$0.020
1.45%
2011-08-17
$0.020
0.91%
2011-05-18
$0.020
0.57%
2011-03-18
$0.020
0.30%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 8,592원
5년 누적 (세후) 5.9만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 16.05% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
LMAT LMAT This Stock
$2.3B36.5 5.6 16.55% 1.01% +3.5%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 르메트르 혈관(LMAT)?

르메트르 혈관(LMAT) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of LMAT?

The market cap of LMAT is approximately $2.3B, ranking 2,011 within its sector.

Does LMAT pay dividends?

LMAT has a dividend yield of approximately 1.01%, with an annual dividend of $1.00.

What is the P/E ratio of LMAT?

LMAT has a P/E ratio of approximately 36.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for LMAT?

LMAT has recorded a 52-week high of $118.01 and a low of $79.00.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.